Search

Displaying results 3291 - 3300 of 7540 in total
  1. Drug

    Omaveloxolone

    go.drugbank.com/drugs/DB12513
    ApprovedInvestigational

    [A257529] In February 2023, omaveloxolone was approved by the FDA for the treatment of Friedreich's ataxia in adults and adolescents aged 16 years and older.

    Synonyms: Propanamide, N-(2-cyano-3,12-dioxo-28-noroleana-1,9(11)-dien-17-yl)-2,2-difluoro-
  2. Drug

    Olmutinib

    go.drugbank.com/drugs/DB13164
    Investigational

    It is available under the brand name Olita made by Hanmi Pharmaceuticals [A19196]. Olmutinib was developed by Hanmi Pharmaceuticals and Boehringer Ingelheim. … Olmutinib is an orally active epidermal growth factor receptor inhibitor used in the treatment of T790M mutation positive non-small cell lung cancer.

  3. Drug

    Quinupramine

    go.drugbank.com/drugs/DB13246
    Approved

    Quinupramine has been approved in France under the brand name Kinupril, as an antidepressant .

    Categories: Non-Selective Monoamine Reuptake Inhibitors, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  4. Drug

    GnRH pharmaccine

    go.drugbank.com/drugs/DB05815
    Experimental

    The pharmaccine is administered intramuscularly to the patient by injection and induces an immune response or production of antibodies in the patient, which neutralize GnRH thus removing it from circulation … The GnRH pharmaccine consists of synthetic peptides (constructed to "look like" GnRH), which are bound chemically to a carrier and suspended in a proprietary "delivery vehicle".

  5. Drug

    MDX-214

    go.drugbank.com/drugs/DB06110
    Experimental

    MDX-214 consists of recombinant human epidermal growth factor (EGF) genetically linked to a fully human antibody fragment that is designed to activate cytotoxic killing of cancer cells by immune effector

  6. Drug

    MLN0415

    go.drugbank.com/drugs/DB05183
    Experimental

    MLN0415 is a novel, small molecule IKK2 inhibitor, discovered by Millennium scientists. … In preclinical studies, MLN0415 was shown to decrease NF-kB activation and down-regulate the expression of a number of inflammatory proteins.

  7. Drug

    OAV201

    go.drugbank.com/drugs/DB17842
    Experimental

    It was first developed by Novartis and investigated for the treatment of Rett syndrome, but further investigation in clinical trials was halted.[L46661] … OAV201 is a non-replicating, recombinant adeno-associated virus serotype 9 (AAV9) containing the human Methyl CpG Binding Protein 2B (MECP2B) cDNA under the control of a segment of the murine MECP2 promoter

  8. Drug

    Cerulenin

    go.drugbank.com/drugs/DB01034
    Experimental

    In fatty acid synthesis, reported to bind in equimolar ratio to b-keto-acyl-ACP synthase. In sterol synthesis, inhibits HMG-CoA synthetase activity. … Cerulenin is an antifungal agent whose activity interferes with or otherwise acts to prevent the formation of fatty acids and sterols.

  9. Drug

    Hydrocortisone butyrate

    go.drugbank.com/drugs/DB14540
    ApprovedVet approved

    Synonyms: 17-O-butyrylcortisol
  10. Drug

    Hydrocortisone probutate

    go.drugbank.com/drugs/DB14543
    ApprovedVet approved